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(79 pts)No HCT
(38 pts)P-value
logistic
regressionUnfavorable cytogenetics (n) 30 (37%) 7 (18%) 0.18
Secondary AML (n) 39 (49%) 15 (39%) 0.32
Early relapse (n) (>5%
marrow blasts within
4.9 months of CR1
(range 0.9-10, median 3.75)0 (0%) 13 (34%) <0.001Twenty-four of the 38 (63%) non-HCTpatients wereHLA-typed
and matched donors were found for 13 of these 24 patients (54%; 5
related, 8 unrelated). Seven of the 14 non-typed patients (50%) had
financial barriers or refusedHLA-typing. Only 2 of these 38 (5%) re-
ceived HCT beyond CR1.
Conclusion: These data suggest that HCT can be performed in
CR1 in the majority of high-risk AML patients in whom it is cur-
rently recommended. Patients in whom HCT is not done are char-
acterized by a poorer performance status (but not older age) and by
early relapse. In the absence of these 2 factors,.75%of patients with
high-risk AML under the age of 75 can receive HCT in CR1. A na-
tional study is planned to assess the extent to which these results can
be generalized.229
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A promising area of investigation in AML is the development of
cancer vaccines that educate host immunity to target leukemia cells,
including the stem cell compartment. Our group has developed
a cancer vaccine in which dendritic cells (DCs) are fused to autolo-
gous tumor cells, resulting in the presentation of multiple tumor an-
tigens and eliciting a broad immune response. A challenge to
developing a more effective tumor vaccine is overcoming inhibitory
pathways, including the PD1/PDL1 pathway, contributing to tu-
mor-mediated immune suppression. We are conducting a clinical
trial in which AML patients who are in remission following chemo-
therapy receive three monthly doses of DC/AML fusion cells alone
(cohort 1) or in conjunction with anti-PD1 antibody, CT-011 (co-
hort 2). To date, 21 patients (mean age 57 years) have been enrolled.
Patients underwent tumor collection from either bone marrow (N5
14), 20 cc of peripheral blood (N 5 5), or leukapheresis product
(N 5 2). The mean tumor yield and viability was 8.43x108 cells
and 99% respectively. Patients achieving remission following che-
motherapy underwent leukapheresis for DC generation. Adherent
peripheral blood mononuclear cells were cultured in the presence
of GM-CSF and IL-4 for 5-7 days, and exposed to TNFa for 48
hours to generate mature DCs. One patient died during induction
chemotherapy, one patient did not collect a sufficient number of tu-
mor cells for vaccine generation, and 3 patients were removed from
study to undergo allogeneic transplantation. Vaccine was generated
in 12 patients at a dose of 5x106 fusions cells, mean fusion efficiency
of 31%, and viability of 87%. As ameasure of their activity as antigen
presenting cells, the capacity of fusion cells to stimulate allogeneic T
cell proliferation ex vivo was quantified. In contrast to the leukemia
cells (mean stimulation index (SI) 4.4), the DC and fusion cells were
potent stimulators (mean SI 24.1 and 15.5, respectively). Vaccination
was initiatedwithin 12 weeks from count recovery following comple-
tion of chemotherapy. 4 patients have completed vaccinations, and 3
are undergoing vaccination. Vaccine related adverse events includedvaccine site reactions, ankle pain and edema. Biopsy of a vaccine site
reaction demonstrated a dense T cell infiltrate. Peripheral blood is
being collected prior to and serially following vaccination. Immune
response targeting leukemia cells, leukemic stem cells, and leukemia
associated antigens will be assessed.230
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CLLpts who are fludarabine-refractory or possess unfavorable cy-
togenetics have short survivals with conventional therapies. Non-
myeloablative allogeneic HCT may provide long-term disease
control. Disease progression is the major risk within the first year
after HCT (median 3.3 months), until development of graft-versus-
leukemia (GVL) effects. Treatment with anti-CD20monoclonal an-
tibody (rituximab) in the early post-transplant period could improve
disease control: 1) directly by antibody-dependent cytotoxicity and
2) indirectly by promoting cross-presentation of cell-derived pep-
tides causing earlier and/or more robust GVL effects. To date, 20
pts have been enrolled on a phase II trial comprising fludarabine,
30 mg/m2 (days -4, -3, and -2) and 2 Gy total body irradiation (day
-1) together with rituximab, 375 mg/m2 (days -3, +10, +24, and
+38). Grafts were from HLA-matched related (n 5 6) or unrelated
(n 5 14) donors. Median age was 61 (range 37-74) years. Pts were
older, had higher comorbidity scores, more frequently received un-
related grafts, and more frequently had unfavorable cytogenetics
compared to a historical control group of 128 pts treated with the
same regimen except for peri-transplant rituximab (Table).
Table. Comparison of Pre-transplant Characteristics Among
Pts Treated with Nonmyeloablative Conditioning and Alloge-
neicHCTEitherWith (n520) orWithout (n5128)Rituximab
No Rituximab Rituximab
(n 5 128),
n (%)
(n 5 20),
n (%) pAge, years $60 32 (26%) 14 (70%) 0.0001
0 51 (32%) 2 (10%)HCT-CI scores 1-2 42 (37%) 7 (35%) 0.05
$3 35 (31%) 11 (55%)Response to last
treatment
prior to HCTRelapse/
refractory73 (57%) 12 (60%) 0.80CR or PR 55 (43%) 8 (40%)
Fludarabine-refractory Yes 117 (91%) 20 (100%) 0.17
Lymph node size
$5 cmYes 33 (26%) 6 (30%) 0.69Campath within
12 months prior
to HCTYes 30 (23%) 5 (25%) 0.88Donor type Unrelated 55 (43%) 14 (70%) 0.02
Chromosomal
abnormalities
Unfavorable* 50 (64%) 19 (95%) 0.0002Favorable† 78 (36%) 1 (5%)*Includes deletion 17p, P53 mutation, deletion 11q23, or more than 3
cytogenetic abnormalities.
†Includes deletion 13q, normal chromosomes, and triosomy 12.
After a median follow up of 13.6 (range: 3.4-26.5) months follow-
ing HCT, none of the 20 pts have experienced progression or
